HtrA2, taming the oncogenic activities of WT1

Cell Cycle

Volumn 9, Issue 13, 2010, Pages 2508-2514

  Hartkamp, Jörg ^a   Roberts, Stefan G E ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Apoptosis; HtrA2; Oncogene; Proteolysis; WT1

Indexed keywords

SERINE PROTEINASE OMI; WT1 PROTEIN;

APOPTOSIS; CELL DIFFERENTIATION; GENE EXPRESSION; HUMAN; NEPHROBLASTOMA; ONCOGENE; PROGNOSIS; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR CELL LINE;

EID: 77955437080     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.13.12060     Document Type: Review

References (75)

1. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005; 5:1-3.
2. Scholz H, Kirschner KM. A role for the Wilms' tumor protein WT1 in organ development. Physiology 2005; 20:54-9. (Pubitemid 40363371)
3. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006; 15:196-201.
4. Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, et al. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004; 165:1943-53. (Pubitemid 39578373)
5. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007; 315:642-5. (Pubitemid 46214707)
6. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21:868-76. (Pubitemid 46672061)
7. Pritchard-Jones K, King-Underwood L. The Wilms tumour gene WT1 in leukaemia. Leuk Lymphoma 1997; 27:207-20. (Pubitemid 27501182)
8. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr, Daniel CW. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997; 94:8132-7. (Pubitemid 27343789)
9. Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, Inoue M, et al. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer 2009; 125:381-7.
10. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007; 9:1-17. (Pubitemid 46965072)
11. Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008; 20:211-20.
12. Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, et al. Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol 2008; 32:701-11.
13. Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, Saavedra-Alonso S, Trejo-Avila LM, Reséndez-Pérez D, et al. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther 2009; 16:892-9.
14. Hartkamp J, Carpenter B, Roberts SGE. The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi. Mol Cell 2010; 37:159-71.
15. Essafi A, Hastie ND. WT1 the oncogene: a tale of death and HtrA. Mol Cell 2010; 37:153-5.
16. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 protooncogene. EMBO J 1999; 18:3990-4003.
17. Richard DJ, Schumacher V, Royer-Pokora B, Roberts SG. Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1. Genes Dev 2001; 15:328-39. (Pubitemid 32155148)
18. Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, et al. Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006; 25:4217-29.
19. Hartkamp J, Roberts SGE. The role of the Wilms' tumour-suppressor protein WT1 in apoptosis. Biochem Soc Trans 2008; 36:629-31.
20. Udtha M, Lee SJ, Alam R, Coombes K, Huff V. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors. Oncogene 2003; 22:3821-6. (Pubitemid 36760745)
21. Han Y, San-Marina S, Liu J, Minden MD. Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene 2004; 23:6933-41. (Pubitemid 39279994)
22. Renshaw J, Orr RM, Walton MI, Te Poele R, Williams RD, Wancewicz EV, et al. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense downregulation of exon 5 alters target gene expression and inhibits cell survival. Mol Cancer Ther 2004; 3:1467-84.
23. Morrison DJ, English MA, Licht JD. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res 2005; 65:8174-82.
24. Simpson LA, Burwell EA, Thompson KA, Shahnaz S, Chen AR, Loeb DM. The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 2006; 107:4695-702. (Pubitemid 43882617)
25. Kim HS, Kim MS, Hancock AL, Harper JC, Park JY, Poy G, et al. Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem 2007; 282:16278-87. (Pubitemid 47100403)
26. Green LM, Wagner KJ, Campbell HA, Addison K, Roberts SGE. Dynamic interaction between WT1 and BASP1 in transcriptional regulation during differentiation. Nucleic Acids Res 2009; 37:431-40.
27. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. WT-1 is required for early kidney development. Cell 1993; 74:679-91. (Pubitemid 23259748)
28. Davies JA, Ladomery M, Hohenstein P, Michael L, Shafe A, Spraggon L, Hastie N. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet 2004; 13:235-46. (Pubitemid 38111361)
29. Gu W, Hu S, Chen Z, Qiu G, Cen J, He B, et al. High expression of WT1 gene in acute myeloid leukemias with more predominant WT1 +17AA isoforms at relapse. Leuk Res 2010; 34:46-9.
30. Hartwig S, Ho J, Pandey P, Macisaac K, Taglienti M, Xiang M, et al. Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development. Development 2010; 137:1189-203.
31. Kim MK, McGarry TJ, O'Broin P, Flatow JM, Golden AA, Licht JD. An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci USA 2009; 106:11154-9.
32. Roberts SGE. Transcriptional regulation by WT1 in development. Curr Opin Genet Dev 2005; 15:542-7.
33. Iben S, Royer-Pokora B. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors. Oncogene 1999; 18:2533-6.
34. McKay LM, Carpenter B, Roberts SGE. Regulation of the Wilms' tumour suppressor protein transcriptional activation domain. Oncogene 1999; 18:6546-54.
35. Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, James DI, et al. BASP1 is a transcriptional cosuppressor for the Wilms' tumour suppressor protein WT1. Mol Cell Biol 2004; 24:537-49.
36. Moribe T, Iizuka N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, et al. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. Int J Oncol 2008; 33:949-58.
37. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102:2951-9.
38. Wang J, Coombes KR, Highsmith WE, Keating MJ, Abruzzo LV. Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics 2004; 20:3166-78.
39. Hartl M, Nist A, Khan MI, Valovka T, Bister K. Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1). Proc Natl Acad Sci USA 2009; 106:5604-9.
40. Maheswaran S, Englert C, Zheng G, Lee SB, Wong J, Harkin DP, et al. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev 1998; 12:1108-20.
41. Galluzzi L, Giordanetto F, Kroemer G. Targeting HSP70 for cancer therapy. Mol Cell 2009; 36:176-7.
42. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995; 9:2143-56.
43. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996; 16:6945-56.
44. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 2003; 278:19995-20005.
45. Scharnhorst V, Dekker P, van der Eb AJ, Jochemsen AG. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. J Biol Chem 1999; 274:23456-62.
46. Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. Hum Mol Genet 2004; 13:405-15.
47. Wang ZY, Qiu QQ, Seufert W, Taguchi T, Testa JR, Whitmore SA, et al. Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9. J Biol Chem 1996; 271:24811-6.
48. Smolen GA, Vassileva MT, Wells J, Matunis MJ, Haber DA. SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res 2004; 64:7846-51.
49. Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ 2008; 15:453-60.
50. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 2002; 277:432-8.
51. Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 2002; 277:439-44.
52. Gray CW, Ward RV, Karran E, Turconi S, Rowles A, Viglienghi D, et al. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem 2000; 267:5699-710.
53. Kuninaka S, Iida SI, Hara T, Nomura M, Naoe H, Morisaki T, et al. Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation. Oncogene 2007; 26:2395-406.
54. Marabese M, Mazzoletti M, Vikhanskaya F, Broggini M. HtrA2 enhances the apoptotic functions of p73 on bax. Cell Death Differ 2008; 15:849-58.
55. Martins LM, Morrison A, Klupsch K, Fedele V, Moisoi N, Teismann P, et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004; 24:9848-62.
56. Jones JM, Datta P, Srinivasula SM, Ji W, Gupta S, Zhang Z, et al. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 2003; 425:721-7.
57. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443:787-95.
58. Moisoi N, Klupsch K, Fedele V, East P, Sharma S, Renton A. Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response. Cell Death Differ 2009; 16:449-64.
59. Challa M, Malladi S, Pellock BJ, Dresnek D, Varadarajan S, Yin YW, et al. Drosophila Omi, a mitochondrial-localized IAP antagonist and proapoptotic serine protease. EMBO J 2007; 26:3144-56.
60. Niksic M, Slight J, Sanford JR, Caceres JF, Hastie ND. The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 2004; 13:463-71.
61. Yang L, Sun M, Sun XM, Cheng GZ, Nicosia SV, Cheng JQ. Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine 212. J Biol Chem 2007; 282:10981-7.
62. Martins LM, Turk BE, Cowling V, Borg A, Jarrell ET, Cantley LC, Downward J. Binding specificity and regulation of the serine protease and PDZ domains of HtrA2/Omi. J Biol Chem 2003; 278:49417-27.
63. Vande Walle L, Van Damme P, Lamkanfi M, Saelens X, Vandekerckhove J, Gevaert K, Vandenabeele P. Proteome-wide Identification of HtrA2/Omi Substrates. J Proteome Res 2007; 6:1006-15.
64. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol 2010; 28:13-9.
65. Savopoulos JW, Carter PS, Turconi S, Pettman GR, Karran EH, Gray CW, et al. Expression, purification and functional analysis of the human serine protease HtrA2. Protein Expr Purif 2000; 19:227-34.
66. Seong YM, Choi JY, Park HJ, Kim KJ, Ahn SG, Seong GH, et al. Autocatalytic processing of HtrA2/Omi is essential for induction of caspase-dependent cell death through antagonizing XIAP. J Biol Chem 2004; 279:37588-96.
67. Park HJ, Kim SS, Seong YM, Kim KH, Goo HG, Yoon EJ, et al. Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease: implications for the physiological function of HtrA2 in the mitochondria. J Biol Chem 2006; 281:34277-87.
68. Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev 2003; 17:1487-96.
69. Srinivasula SM, Gupta S, Datta P, Zhang Z, Hegde R, Cheong N, et al. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem 2003; 278:31469-72.
70. Trencia A, Fiory F, Maitan MA, Vito P, Barbagallo AP, Perfetti A, et al. Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein ped/pea-15. J Biol Chem 2004; 279:46566-72.
71. Cilenti L, Soundarapandian MM, Kyriazis GA, Stratico V, Singh S, Gupta S, et al. Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J Biol Chem 2004; 279:50295-301.
72. Vande Walle L, Wirawan E, Lamkanfi M, Festjens N, Verspurten J, Saelens X, et al. The mitochondrial serine protease HtrA2/Omi cleaves RIP1 during apoptosis of Ba/F3 cells induced by growth factor withdrawal. Cell Res 2010; 20:421-33.
73. Wang CY, Lin YS, Su WC, Chen CL, Lin CF. Glycogen synthase kinase-3 and Omi/HtrA2 induce annexin A2 cleavage followed by cell cycle inhibition and apoptosis. Mol Biol Cell 2009; 20:4153-61.
74. Park HM, Kim GY, Nam MK, Seong GH, Han C, Chung KC, et al. The serine protease HtrA2/Omi cleaves Parkin and irreversibly inactivates its E3 ubiquitin ligase activity. Biochem Biophys Res Commun 2009; 387:537-42.
75. Balakrishnan MP, Cilenti L, Mashak Z, Popat P, Alnemri ES, Zervos AS. THAP5 is a human cardiac-specific inhibitor of cell cycle that is cleaved by the proapoptotic Omi/HtrA2 protease during cell death. Am J Physiol Heart Circ Physiol 2009; 297:643-53.